Login / Signup

Sequential vaccinations with divergent H1N1 influenza virus strains induce multi-H1 clade neutralizing antibodies in swine.

Kristien Van ReethAnna ParysJosé Carlos Mancera GraciaIvan TrusKoen ChiersPhilip MeadeSean T H LiuPeter PaleseFlorian KrammerElien Vandoorn
Published in: Nature communications (2023)
Vaccines that protect against any H1N1 influenza A virus strain would be advantageous for use in pigs and humans. Here, we try to induce a pan-H1N1 antibody response in pigs by sequential vaccination with antigenically divergent H1N1 strains. Adjuvanted whole inactivated vaccines are given intramuscularly in various two- and three-dose regimens. Three doses of heterologous monovalent H1N1 vaccine result in seroprotective neutralizing antibodies against 71% of a diverse panel of human and swine H1 strains, detectable antibodies against 88% of strains, and sterile cross-clade immunity against two heterologous challenge strains. This strategy outperforms any two-dose regimen and is as good or better than giving three doses of matched trivalent vaccine. Neutralizing antibodies are H1-specific, and the second heterologous booster enhances reactivity with conserved epitopes in the HA head. We show that even the most traditional influenza vaccines can offer surprisingly broad protection if they are administered in an alternative way.
Keyphrases
  • escherichia coli
  • dengue virus
  • endothelial cells
  • saccharomyces cerevisiae
  • transcription factor
  • zika virus
  • pluripotent stem cells